



Ref. No.: EIKO/BSE/2022-23/31

Dated: 21st October 2022

To,
Corporate Services Department,
BSE Limited,
P J Towers, 1st Floor,
Dalal Street, Fort, Mumbai - 400001.

Sub: Outcome of Board Meeting held today i.e., October 21, 2022.

Ref: Eiko LifeSciences Limited

BSE Scrip Code: EIKO 540204

Dear Sir/Madam,

Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), and amendments thereto, this is to inform that the Meeting of the Board of Directors of the Company held today i.e., on Friday, 21st October, 2022 at 4.00 P.M. the Board, inter-alia, considered and approved the Unaudited Financial Results for the Quarter and half year ended 30th September 2022

The Statutory Auditors have carried out a "Limited Review" of the Unaudited Financial Results for the Quarter and half year ended 30th September 2022

Further, Pursuant to the Regulation 33 of the Listing Regulations, we are enclosing herewith a copy of the Unaudited Financial Results and Limited Review Report of the Statutory Auditors of the Company

The said results shall be published in one English and one vernacular newspaper as required.

This intimation is also available on the Company's website at www.eikolifescienceslimited.com

The meeting of Board of Directors concluded at 4:45 P.M.

Please take the same on your records.

Thanking you.

Yours Sincerely,

For **EIKO LIFESCIENCES LIMITED**

Avi Mundecha
Company Secretary
ACS-65529

Encl: same as above

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2022

(₹ in Lakhs except EPS)

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		30.09.2022	30.06.2022	30.09.2021	30.09.2022	30.09.2021	31-03-2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1.00	Revenue from operations	431.05	304.07	609.43	735.12	1,453.97	2,541.19
	Other income	22.57	23.50	19.43	46.07	32.08	67.33
	Total revenue	453.62	327.56	628.86	781.19	1,486.04	2,608.52
2.00	Expenses	-					
	Cost of Material consumed	330.41	209.61	596.24	540.03	1,362.27	2,504.78
	Changes in inventories of finished stock and work-in-progress	56.24	35.75	(56.38)	91.98	(81.55)	(246.62)
	Employee benefits expense	6.78	7.75	5.19	14.52	13.83	27.70
	Depreciation and amortization expense	15.77	15.74	16.06	31.50	25.34	56.24
	Finance Cost	1.49	8.77	18.57	10.26	23.12	46.42
	Other expenses	23.11	38.88	19.93	61.99	60.17	125.80
	Total expenses	433.79	316.49	599.60	750.29	1,403.17	2,514.32
3.00	Profit/(Loss) from ordinary activities before tax	19.83	11.07	29.26	30.90	82.88	94.20
4.00	Tax expense:	-					
	(1) Current tax	-	-	1.80	-	7.56	-
	(2) Earlier year's Tax	-	-	0.25	-	0.25	0.25
	(4) Deferred tax	4.92	2.79	5.34	7.70	13.06	23.38
5.00	Profit/(Loss) from ordinary activities after tax	14.91	8.28	21.88	23.19	62.00	70.57
6.00	Other Comprehensive Income (OCI)						
	<u>Item that will not be reclassified to profit or loss</u>						
	Gain/(Loss) on recognised on fair valuation of Financial Assets	4.21	(1.01)	(1.24)	3.21	(1.30)	(2.19)
	Income tax relating to these items	(1.06)	0.25	0.31	(0.81)	0.33	0.55
	Total Other Comprehensive Income (OCI)	3.15	(0.75)	(0.93)	2.40	(0.97)	(1.64)
	Profit/(Loss) for the Period	18.07	7.53	20.95	25.59	61.03	68.94
	Paid up Equity Share Capital (Face Value of Rs. 10 each)	831.63	831.63	831.63	831.63	831.63	831.63
7	Earning Per Share (EPS) (Not annualised)						
	(1) Basic	0.18	0.10	0.26	0.28	0.85	0.90
	(2) Diluted	0.18	0.10	0.26	0.28	0.85	0.90



Notes:

- 1 The above Financial Results for the quarter ended 30th September 2022 have been reviewed and recommended by Audit Committee and has been approved by the Board of Directors at its Meeting held on Friday, 21st October 2022. The Statutory Auditors have carried out Limited Review of above results and expressed an unmodified opinion on these financial results.
- 2 The Company has single business segment namely "**Speciality & Fine Chemicals**" therefore in the context of Ind As 108, disclosure of segment information is not applicable.
- 3 Previous quarter figures have been regrouped reclassified wherever necessary, to make them comparable.

For Eiko Lifesciences Limited

Laxmikant Kabra
Chairman
DIN: 00061346



Place: Thane

Date: 21st October 2022

Disclosure of Assets and Liabilities as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as of 30th September 2022

(₹ in Lakhs)

Particulars	As at 30-09-2022	As at 31-03-2022
ASSETS		
Non-current assets		
Property, Plant and Equipment	1,401.42	1,428.92
<u>Financial Assets</u>	-	-
Investments	0.27	20.02
Loans	134.35	230.26
Other Financial Assets	587.69	566.65
Deferred Tax Asset	-	-
	2,123.73	2,245.85
Current assets		
Inventories	236.66	545.75
<u>Financial Assets</u>	-	-
Trade Receivables	440.42	456.23
Cash and cash equivalents	82.51	21.73
Other Current Financial Assets	29.61	22.83
Other Current Assets	96.67	196.98
	885.87	1,243.53
TOTAL ASSET	3,009.59	3,489.37
EQUITY AND LIABILITIES		
EQUITY		
Equity Share capital	831.63	831.63
Other Equity	2,056.92	2,031.32
Share Application Money Pending for Allotment	-	-
	2,888.55	2,862.95
LIABILITIES		
Non-current liabilities		
<u>Financial Liabilities</u>		
Non Current Borrowings	9.17	5.36
Deferred Tax Liabilities	28.98	20.47
	38.15	25.83
Current liabilities		
<u>Financial Liabilities</u>		
1. Current Borrowing	0.78	449.96
2. Trade Payables	56.02	134.85
3. Other Financial Liabilities	21.46	7.45
Current Tax liability	-	-
Provisions	1.37	3.35
Other current Liability	3.28	4.99
	82.90	601
TOTAL LIABILITIES	3,009.59	3,489.37

For Eiko Lifesciences Limited

L.K. Kabra

Laxmikant Kabra
Chairman
DIN: 00061346



Place: Thane
Date: 21st October 2022

Disclosure of cashflow as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended 30th September 2022

(₹ in Lakhs)		
Particulars	Period Ended 30.09.2022	Year ended 31.03.2022
<u>A. CASH FLOW FROM OPERATING ACTIVITIES</u>		
Net (loss) / profit before tax	30.90	94.20
Adjustments for		
Depreciation and Amortisation Expense	31.50	56.24
Interest Income classified as investing cash flow	(34.84)	(63.83)
Profit on Sales of Investments	(3.15)	-
Finance Costs	10.26	46.42
Dividend Income	0.00	(0.40)
Operating profit before working capital changes	34.67	132.63
Working capital adjustments: -		
Increase / (Decrease) in Trade and Other Payables	(78.83)	(54.65)
Increase / (Decrease) in Provisions	(1.98)	(26.64)
Increase / (Decrease) in Other Financial Liabilities	14.01	0.65
Increase / (Decrease) in Other Current Liabilities	(1.72)	3.26
(Increase) / Decrease in Inventories	309.09	(539.40)
(Increase) / Decrease in Trade Receivables	15.81	(114.76)
(Increase) / Decrease in Other Current Assets	100.31	(152.71)
Cash generated from / (used in) operations	274.37	(751.62)
Direct taxes paid (Net of Refunds)		(21.11)
Net cash (used in) / from generated from operating activities	274.37	(772.73)
<u>B. CASH FLOW FROM INVESTING ACTIVITIES</u>		
- Sale/(Purchase) of Investments	26.10	(0.26)
- Sale/(Purchase) of Fixed Assets	(4.00)	(15.46)
Loans and Advances	68.10	10.72
Interest Income	34.84	63.83
Dividend received	0.00	0.40
Net cash (used in) / generated from investing activities	242.04	59.23
<u>C. CASH FLOW FROM FINANCING ACTIVITIES</u>		
- Proceeds from issue of shares	-	94.99
- Interest paid	(10.26)	(46.42)
Proceeds /(Repayment) from borrowings	(445.38)	279.45
Net cash (used in) / from financing activities	(455.63)	328.02
Net decrease in cash and cash equivalents (A+B+C)	60.78	(385.47)
Cash and cash equivalents at the beginning of the year	21.73	407.20
Cash and cash equivalents at the end of the year	82.51	21.73

For Eiko Lifesciences Limited

L.K. Kabra

Laxmikant Kabra
Chairman
DIN: 00061346



Place: Thane
Date: 21st October 2022




Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**To the Board of Directors
Eiko Lifesciences Limited
(Formerly known as Narendra Investments (Delhi) Limited)**

1. We have reviewed the accompanying statement of Unaudited Financial Results of **Eiko Lifesciences Limited** (Formerly known as Narendra Investments (Delhi) Limited) (the "Company") for the quarter and half year ended September 30, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable Principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement

For Thanawala & Company
Chartered Accountants
Firm Reg. No.: 110948W


CA Vijay K. Thanawala
Proprietor
Membership No.: 015632



Place: Mumbai
Date: 21st October 2022

UDIN: 22015632BAOZNB4414